Evidence map›Paper›PMID 37646958›Full record

ArticleInvestigational new drugs2023

A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer.

Z Sun, C Gu, X Wang, A Shang, W Quan, J Wu, P Ji, Y Yao, W Liu, D Li

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Z Sun *Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
C Gu *Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
X WangDepartment of Pharmacy, Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
A ShangDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
W QuanDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
J WuDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
P JiDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Y YaoDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
W LiuDepartment of General Surgery, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China. lwf112@163.com.
D LiDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China. lidong@tongji.edu.cn.
Tongji University · CNTongji Hospital · CNThe First People’s Hospital of Lianyungang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we generated a novel bispecific antibody (BsAb) simultaneously targeting both c-MET and PD-1 (PDCD1), which can bridge T cells and c-MET positive tumor cells. However, the specific mechanisms and antitumor activities of the BsAb against c-MET/PD-L1 (CD274) positive colorectal cancer (CRC) is not completely understood. In this study, in addition to the tumor intrinsic mechanism investigation with molecular biology assay in vitro, a humanized mouse model was used to evaluate antitumor activity of the BsAb in vivo. The BsAb could inhibit c-MET/PD-L1

Indexed as

Antibodies, BispecificAntineoplastic Agents, ImmunologicalB7-H1 AntigenColorectal NeoplasmsProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-metAnimalsCell Line, TumorCell MovementFemaleHCT116 CellsHumansMiceXenograft Model Antitumor AssaysAntibodies, BispecificAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanMET protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-metBispecific antibodyc-METColorectal cancerFocal adhesion kinaseGRB2-associated-binding protein 1PD-1

Identifiers

PMID37646958
OpenAlexW4386272594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.